Darunawir + kobicystat i Oksykodon: interakcja
Darunawir + kobicystat i Oksykodon: obie etykiety FDA opisują to połączenie najsilniejszymi sformułowaniami, takimi jak przeciwwskazanie, ostrzeżenie w ramce lub zalecenie, aby go unikać.
Nie łączyć bez zaleceń lekarza przepisującego leki. Poniższe sformułowania z etykiety to najsilniejsze, jakich używa FDA.
Co mówią etykiety FDA
Źródło: etykieta leku Oksykodon (Oxycodone Hydrochloride) · obowiązuje od 2026-04-16
Cytochrome P450 3A4 Interaction The concomitant use of Oxycodone Hydrochloride Oral Solution with all cytochrome P450 3A4 inhibitors may result in an increase in oxycodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression.
Regularly evaluate patients receiving Oxycodone Hydrochloride Oral Solution and any CYP3A4 inhibitor or inducer [see Warnings and Precautions (5.7) , Drug Interactions (7) , Clinical Pharmacology (12.3) ].
The concomitant use with CYP3A4 inhibitors (or discontinuation of CYP3A4 inducers) can result in a fatal overdose of oxycodone.
Risks of Concomitant Use or Discontinuation of Cytochrome P450 3A4 Inhibitors and Inducers Concomitant use of Oxycodone Hydrochloride Oral Solution with a CYP3A4 inhibitor, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may increase plasma concentrations of oxycodone…
When using Oxycodone Hydrochloride Oral Solution with CYP3A4 inhibitors or discontinuing CYP3A4 inducers in Oxycodone Hydrochloride Oral Solution-treated patients, evaluate patients at frequent intervals and consider dosage reduction of Oxycodone Hydrochloride Oral Solution until stable drug effects are achieved [see Dosage and Administration (2.1) , Drug Interactions…
Źródło: etykieta leku Darunawir + kobicystat (PREZCOBIX) · obowiązuje od 2026-02-01
Narcotic analgesics metabolized by CYP3A: e.g. fentanyl, oxycodone ↑ fentanyl ↑ oxycodone Careful monitoring of therapeutic effects and adverse reactions associated with CYP3A-metabolized narcotic analgesics (including potentially fatal respiratory depression) is recommended with co-administration. tramadol ↑ tramadol A dose decrease may be needed for tramadol…
…elbasvir/grazoprevir Lipid modifying agents: lomitapide, lovastatin, simvastatin Opioid Antagonist: naloxegol PDE-5 inhibitor: sildenafil when used for treatment of pulmonary arterial hypertension Sedatives/hypnotics: orally administered midazolam, triazolam PREZCOBIX or PREZCOBIX PED is contraindicated in patients receiving certain co-administered drugs for which altered plasma…
Opioid Antagonist naloxegol ↑ naloxegol Co-administration of PREZCOBIX or PREZCOBIX PED and naloxegol is contraindicated due to potential for precipitating opioid withdrawal symptoms.
Sedatives/hypnotics: orally administered midazolam, triazolam ↑ midazolam ↑ triazolam Co-administration is contraindicated due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.
Narcotic analgesic for treatment of opioid dependence: buprenorphine, buprenorphine/naloxone, methadone buprenorphine or buprenorphine/ naloxone: effects unknown methadone: effects unknown Initiation of buprenorphine, buprenorphine/naloxone or methadone in patients taking PREZCOBIX or PREZCOBIX PED : Carefully titrate the dose of buprenorphine, buprenorphine/naloxone…
Więcej leków niż te dwa? Interakcje się kumulują. Całą listę można sprawdzić jednocześnie; pozostaje ona w przeglądarce.
Otwórz w wyszukiwarceTo nie jest porada medyczna. Interaction Checker cytuje tekst etykiet FDA i karty informacyjne NIH. To, czy interakcja ma znaczenie w konkretnym przypadku, zależy od dawek, pory przyjmowania, czynności nerek i wątroby oraz innych schorzeń. Należy to potwierdzić u farmaceuty lub lekarza przepisującego leki.